Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Shao, Yu‐Yun; Wang, Shen-Yung; Lin, Shi‐Ming; Chen, Kuan-Yang; Tseng, Jeng‐Hwei; Ho, Ming-Chih; Lee, Rheun‐Chuan; Liang, Po-Chin; Liao, Li‐Ying; Huang, Kai-Wen; Hu, Jianhe; Liang, Ja-Der; Kee, Kwong‐Ming; Lin, Chih–Lin; Wang, Chung-Kwe; Lu, Sheng–Nan; Wang, Jing‐Houng; Lee, Wei‐Chen; Chen, Chien‐Hung; Liu, Chun‐Jen; Huang, Yi‐Hsiang; Wang, Chia-Chi; Wang, Tsang-En; Chuang, Po‐Heng; Dai, Chia‐Yen; Hsu, Chiun; Chen, San‐Chi; Hsieh, Chia-Hsun

doi:10.1016/j.jfma.2020.10.031

Cited by 91 publications

(81 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some developed countries, the mortality rate of HCC-related cirrhosis is increasing (23). Table 1 lists the risk factors for liver cirrhosis caused by hepatitis in various contexts, of which liver cirrhosis is the most frequent (24)(25)(26)(27)(28)(29)(30)(31)(32)(33). Compared with patients with HBV, patients with HCV seem to be more likely to develop liver cirrhosis.…”

Section: Liver Cirrhosismentioning

confidence: 99%

Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common cancer in the world, and its incidence is increasing yearly. Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection are important causes of HCC. Liver cirrhosis, age, sex, smoking and drinking, and metabolic risk factors will increase the risk of cancer in HBV/HCV patients. And viral load, APRI, FIB-4, and liver stiffness can all predict the risk of HCC in patients with viral infection. In addition, effective prevention strategies are essential in reducing the risk of HCC. The prevention of HCC involves mainly tertiary prevention strategies, while the primary prevention is based on standardized vaccine injections to prevent the occurrence of HBV/HCV. Eliminating the route of transmission and vaccination will lead to a decrease in the incidence of HCC. Secondary prevention involves effective antiviral treatment of HBV/HCV to prevent the disease from progressing to HCC, and tertiary prevention is actively treating HCC to prevent its recurrence.

show abstract

Section: Liver Cirrhosismentioning

confidence: 99%

Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The commonly used methods are Cancer of the Liver Italian Program (CLIP) score, Barcelona Clinic Liver Cancer (BCLC) staging, Tumor/Node/Metastasis (TNM) classification system, and Hong Kong Liver Cancer (HKLC) staging [9]. According to the management consensus guideline for HCC, different stages of HCC should be addressed by different treatment strategies, such as surgery, local ablation, transarterial therapies (including transarterial chemoembolization (TACE)), systemic treatment, radiotherapy, and prevention [10]. However, we currently lack an effective systemic chemotherapy, immunotherapy, or targeted therapy for patients with advanced HCC.…”

Section: Pathological Characteristics and Clinical Development Of Hccmentioning

confidence: 99%

Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer

Huang

Liao

Huang

et al. 2021

Cancers

View full text Add to dashboard Cite

Liver cancer is the leading cause of cancer-related mortality in the world. This mainly reflects the lack of early diagnosis tools and effective treatment methods. MicroRNAs (miRNAs) are a class of non-transcribed RNAs, some of which play important regulatory roles in liver cancer. Here, we discuss microRNAs with key impacts on liver cancer, such as miR-122, miR-21, miR-214, and miR-199. These microRNAs participate in various physiological regulatory pathways of liver cancer cells, and their modulation can have non-negligible effects in the treatment of liver cancer. We discuss whether these microRNAs can be used for better clinical diagnosis and/or drug development. With the advent of novel technologies, fast, inexpensive, and non-invasive RNA-based biomarker research has become a new mainstream approach. However, the clinical application of microRNA-based markers has been limited by the high sequence similarity among them and the potential for off-target problems. Therefore, researchers particularly value microRNAs that are specific to or have special functions in liver cancer. These include miR-122, which is specifically expressed in the liver, and miR-34, which is necessary for the replication of the hepatitis C virus in liver cancer. Clinical treatment drugs have been developed based on miR-34 and miR-122 (MRX34 and Miravirsen, respectively), but their side effects have not yet been overcome. Future research is needed to address these weaknesses and establish a feasible microRNA-based treatment strategy for liver cancer.

show abstract

“…MTAs are generally used in patients with Child-Pugh A HCC, whereas the use of MTAs in patients with Child-Pugh B HCC remains controversial. Some Asian guidelines recommended that sorafenib is considered in selected patients with Child-Pugh B (e.g., score, 7 points) [18,33,34,66,67], although sorafenib treatment significantly worsened survival in patients with Child-Pugh B HCC compared to those with Child-Pugh A HCC [68]. In contrast, patients with Child-Pugh B HCC (score 7 or 8 points) are candidates for HAIC [43].…”

Section: Clinical Benefits and Disadvantages Of Haicmentioning

confidence: 99%

Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

Recent success of systemic therapeutic agents, including combination immunotherapy, could promote a change in the treatment strategy in patients with advanced hepatocellular carcinoma (HCC). Although hepatic arterial infusion chemotherapy (HAIC) is a treatment option for advanced HCC in Japan, it is not recommended by other guidelines. We discuss the clinical benefits of HAIC compared to sorafenib. The clinical benefits of HAIC are as follows: 1) even a patient with Child–Pugh B HCC (7 or 8 points) is a candidate for HAIC; 2) Child–Pugh scores barely decline with the use of HAIC compared with sorafenib; 3) HAIC is highly effective in patients with vascular invasion compared with sorafenib; and 4) survival in patients receiving HAIC may not be associated with skeletal muscle volume. In contrast, the disadvantages are problems related with the reservoir system. HAIC has clinical benefits in a subpopulation of patients without extrahepatic metastasis with Child–Pugh A HCC and vascular invasion (especially primary branch invasion or main portal vein invasion) or with Child–Pugh B HCC.

show abstract

Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Cited by 91 publications

References 69 publications

Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma

Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma

Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer

Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma

Contact Info

Product

Resources

About